What triggered AstraZeneca shares' latest price pullback

Traders Union
All News
Financial News
Astrazeneca slips 2.07% today

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Ciaran Ryan

02.06.2026

What triggered AstraZeneca shares' latest price pullback — Astrazeneca slips 2.07% today

AstraZeneca PLC (AZN) closed at GBX 13,156.00, slipping 2.07% on the day and remaining below its 20-day, 50-day, and 200-day simple moving averages. The asset continues to show short- and medium-term downside pressure, with longer-term support close to current price levels.

AZN price prediction

24H -0.84%

GBX 13466

48H -0.48%

GBX 13515

7D 0.8%

GBX 13689

1M -0.38%

GBX 13528.85

3M 4.58%

GBX 14201.44

6M 16.48%

GBX 15818.62

12M 28.05%

GBX 17389.73

Detailed

Current price: GBX 13580 370.00 2.80%

Closed 06/04

Daily range 13168.00

13592.00

Weekly range 11232.00

13912.00

Highlights

AstraZeneca announced positive Phase III results for anselamimab in a rare disease and improved survival in liver cancer with the STRIDE regimen plus lenvatinib and TACE.
The company added 14,120 new ordinary shares via employee programs, bringing total shares outstanding to 1,551,009,750 as of May 31, 2026.
AstraZeneca trades below major moving averages with persistent downside momentum, oversold conditions, and an expected five-session range of GBX 12,847.00 to GBX 13,362.00.

Positive trial results offset by new share issuance and selling pressure

AstraZeneca reported positive topline Phase III results from its CARES program evaluating anselamimab in a rare disease setting. The company increased its listing by 14,120 new ordinary shares through employee schemes, raising total shares in issue to 1,551,009,750 as of May 31, 2026. Successful outcomes were also reported from the Phase 3 EMERALD-3 trial, where the STRIDE regimen combined with lenvatinib and TACE demonstrated improved progression-free survival in patients with unresectable liver cancer, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, highlights AstraZeneca’s weak technical structure below all key moving averages. He notes persistent negative momentum, with MACD and ADX confirming strong downward pressure. The analyst points out that recent positive trial news has failed to shift bearish sentiment, as intraday indicators remain deeply negative and oversold. Medium-term downside risk dominates, especially while GBX 12,847.00 support is threatened. "Without a clear reversal signal or renewed buying interest, I remain cautious and see ongoing vulnerability to further declines," Kharitonov warns.

Viktoras Karapetjanc, expert at Traders Union, sees a constructive picture for AstraZeneca, reinforced by major clinical successes and ongoing share issuance under employee schemes. He emphasizes that recent Phase III results bolster the company’s innovation pipeline and long-term growth. Despite a period of downside, the analyst finds significant opportunity for a rebound if prices stabilize above support. Karapetjanc states confidently, "Fundamental drivers remain strong and I believe the bullish structure will reassert itself, offering attractive setups for medium-term investors."

Technical momentum signals deepen as sellers maintain intraday control

AstraZeneca is trading below its 20-day, 50-day, and 200-day simple moving averages (GBX 13,694.19, GBX 14,180.04, and GBX 13,502.88, respectively), indicating prevailing short- and medium-term downside pressure with longer-term support close to the current price region. The nearest dynamic support is provided by the Ichimoku Kijun at GBX 13,178.00, with recent price action suggesting sellers remain in control. Momentum signals remain negative with the Moving Average Convergence Divergence (MACD) forecasting a strong sell and the Average Directional Index (ADX) showing a strong trend at 40.92. The Relative Strength Index (RSI) and Commodity Channel Index (CCI) both indicate the stock is trending lower, while Stochastic RSI, CCI, and Bull/Bear Power (BBP) highlight oversold conditions. Sellers continue to dominate intraday momentum as shown by BBP deep in negative territory. The overall intraday tone stays heavy with persistent pressure after the open, and short-term indicators show no divergence — all point to ongoing weakness.

Earlier, analysts noted that AstraZeneca shares were under sustained selling pressure despite ongoing advances in its late-stage oncology and specialty therapeutics pipeline. The current backdrop of persistent downside momentum, even in the face of positive clinical developments and incremental share issuance, highlights the importance of monitoring upcoming support around GBX 12,847.00 for signals of either renewed downside risk or potential stabilization.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.